Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Irene Gañán‐Gómez(The University of Texas MD Anderson Cancer Center), Simona Colla(The University of Texas MD Anderson Cancer Center)
Cited by 81
Related Papers
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
|Cell Reports Medicine|2024|14
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation
|Nature Genetics|2025|10
Clonal evolution of hematopoietic stem cells after cancer chemotherapy
|bioRxiv (Cold Spring Harbor Laboratory)|2024|6